trending Market Intelligence /marketintelligence/en/news-insights/trending/f-X9onAlHv0GOHarGGta3w2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Santé Ventures pulls in $250M for 3rd healthcare, life science fund

Blog

Latin American and Caribbean Market Considerations Blog Series: Focus on IFRS 9

Blog

Banking Essentials Newsletter: April Edition - Part 2

Blog

The Evolution of Cloud Banking: Successful Implementation & Frameworks

Blog

Banking Essentials Newsletter - April Edition


Santé Ventures pulls in $250M for 3rd healthcare, life science fund

Santé Ventures LLC raised $250 million for Sante Health Ventures III LP at final close.

The fund, which surpassed its target by 25%, obtained commitments from more than 30 limited partners, including the Pennsylvania Public School Employees' Retirement System. Other sponsors include sovereign wealth funds, Europe- and Asia-based investors, and several new healthcare delivery systems. The vehicle will build a portfolio of up to 25 investments.

It has committed approximately 6.5% of capital to several investments, including Cryosa Inc., which provides treatment for sleep apnea; DyaMX Inc., which offers treatment for Type II diabetes; and Geneos Therapeutics Inc., a neoantigen-based personalized cancer therapy provider.

Santé is a Texas-based venture capital firm focused on early-stage companies in the healthcare and life sciences markets.